Literature DB >> 29409688

Classification and molecular pathogenesis of NBIA syndromes.

Ivano Di Meo1, Valeria Tiranti2.   

Abstract

Brain iron accumulation is the hallmark of a group of seriously invalidating and progressive rare diseases collectively denominated Neurodegeneration with Brain Iron Accumulation (NBIA), characterized by movement disorder, painful dystonia, parkinsonism, mental disability and early death. Currently there is no established therapy available to slow down or reverse the progression of these conditions. Several genes have been identified as responsible for NBIA but only two encode for proteins playing a direct role in iron metabolism. The other genes encode for proteins either with various functions in lipid metabolism, lysosomal activity and autophagic processes or with still unknown roles. The different NBIA subtypes have been classified and denominated on the basis of the mutated genes and, despite genetic heterogeneity, some of them code for proteins, which share or converge on common metabolic pathways. In the last ten years, the implementation of genetic screening based on Whole Exome Sequencing has greatly accelerated gene discovery, nevertheless our knowledge of the pathogenic mechanisms underlying the NBIA syndromes is still largely incomplete.
Copyright © 2018 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bioenergetic metabolism; Iron; Neurodegeneration; Pathogenic mechanisms

Mesh:

Year:  2018        PMID: 29409688     DOI: 10.1016/j.ejpn.2018.01.008

Source DB:  PubMed          Journal:  Eur J Paediatr Neurol        ISSN: 1090-3798            Impact factor:   3.140


  10 in total

1.  Novel case of neurodegeneration with brain iron accumulation 4 (NBIA4) caused by a pathogenic variant affecting splicing.

Authors:  Peter Sparber; Andrey Marakhonov; Alexandra Filatova; Inna Sharkova; Mikhail Skoblov
Journal:  Neurogenetics       Date:  2018-11-03       Impact factor: 2.660

2.  SPG43 and ALS-like syndrome in the same family due to compound heterozygous mutations of the C19orf12 gene: a case description and brief review.

Authors:  Gauthier Remiche; Isabelle Vandernoot; Niloufar Sadeghi-Meibodi; Laurence Desmyter
Journal:  Neurogenetics       Date:  2021-01-04       Impact factor: 2.660

Review 3.  Iron Homeostasis in the CNS: An Overview of the Pathological Consequences of Iron Metabolism Disruption.

Authors:  Christina A Porras; Tracey A Rouault
Journal:  Int J Mol Sci       Date:  2022-04-19       Impact factor: 6.208

4.  MINPP1 prevents intracellular accumulation of the chelator inositol hexakisphosphate and is mutated in Pontocerebellar Hypoplasia.

Authors:  Ekin Ucuncu; Karthyayani Rajamani; Miranda S C Wilson; Daniel Medina-Cano; Nami Altin; Pierre David; Giulia Barcia; Nathalie Lefort; Céline Banal; Marie-Thérèse Vasilache-Dangles; Gaële Pitelet; Elsa Lorino; Nathalie Rabasse; Eric Bieth; Maha S Zaki; Meral Topcu; Fatma Mujgan Sonmez; Damir Musaev; Valentina Stanley; Christine Bole-Feysot; Patrick Nitschké; Arnold Munnich; Nadia Bahi-Buisson; Catherine Fossoud; Fabienne Giuliano; Laurence Colleaux; Lydie Burglen; Joseph G Gleeson; Nathalie Boddaert; Adolfo Saiardi; Vincent Cantagrel
Journal:  Nat Commun       Date:  2020-11-30       Impact factor: 14.919

5.  Long-Term Neuroradiological and Clinical Evaluation of NBIA Patients Treated with a Deferiprone Based Iron-Chelation Therapy.

Authors:  Nicola Romano; Giammarco Baiardi; Valeria Maria Pinto; Sabrina Quintino; Barbara Gianesin; Riccardo Sasso; Andrea Diociasi; Francesca Mattioli; Roberta Marchese; Giovanni Abbruzzese; Antonio Castaldi; Gian Luca Forni
Journal:  J Clin Med       Date:  2022-08-03       Impact factor: 4.964

6.  Stem Cell Modeling of Neuroferritinopathy Reveals Iron as a Determinant of Senescence and Ferroptosis during Neuronal Aging.

Authors:  Anna Cozzi; Daniel I Orellana; Paolo Santambrogio; Alicia Rubio; Cinzia Cancellieri; Serena Giannelli; Maddalena Ripamonti; Stefano Taverna; Giulia Di Lullo; Ermanna Rovida; Maurizio Ferrari; Gian Luca Forni; Chiara Fiorillo; Vania Broccoli; Sonia Levi
Journal:  Stem Cell Reports       Date:  2019-10-03       Impact factor: 7.765

7.  Brain iron content in systemic iron overload: A beta-thalassemia quantitative MRI study.

Authors:  Renzo Manara; Sara Ponticorvo; Immacolata Tartaglione; Gianluca Femina; Andrea Elefante; Camilla Russo; Pasquale Alessandro Carafa; Mario Cirillo; Maddalena Casale; Angela Ciancio; Rosanna Di Concilio; Elisa De Michele; Nikolaus Weiskopf; Francesco Di Salle; Silverio Perrotta; Fabrizio Esposito
Journal:  Neuroimage Clin       Date:  2019-10-25       Impact factor: 4.881

8.  VAC14 syndrome in two siblings with retinitis pigmentosa and neurodegeneration with brain iron accumulation.

Authors:  Gholson J Lyon; Elaine Marchi; Joseph Ekstein; Vardiella Meiner; Yoel Hirsch; Sholem Scher; Edward Yang; Darryl C De Vivo; Ricardo Madrid; Quan Li; Kai Wang; Andrea Haworth; Ilana Chilton; Wendy K Chung; Milen Velinov
Journal:  Cold Spring Harb Mol Case Stud       Date:  2019-12-13

9.  Novel deep intronic mutation in PLA2G6 causing early-onset Parkinson's disease with brain iron accumulation through pseudo-exon activation.

Authors:  Ivano Di Meo; Valeria Tiranti; Chiara Cavestro; Celeste Panteghini; Chiara Reale; Alessia Nasca; Silvia Fenu; Ettore Salsano; Luisa Chiapparini; Barbara Garavaglia; Davide Pareyson
Journal:  Neurogenetics       Date:  2021-08-13       Impact factor: 2.660

10.  A comprehensive phenotypic characterization of a whole-body Wdr45 knock-out mouse.

Authors:  Caroline A Biagosch; Silvia Vidali; Holger Prokisch; Arcangela Iuso; Michael Faerberboeck; Svenja-Viola Hensler; Lore Becker; Oana V Amarie; Antonio Aguilar-Pimentel; Lillian Garrett; Tanja Klein-Rodewald; Birgit Rathkolb; Enrica Zanuttigh; Julia Calzada-Wack; Patricia da Silva-Buttkus; Jan Rozman; Irina Treise; Helmut Fuchs; Valerie Gailus-Durner; Martin Hrabě de Angelis; Dirk Janik; Wolfgang Wurst; Johannes A Mayr; Thomas Klopstock; Thomas Meitinger
Journal:  Mamm Genome       Date:  2021-05-27       Impact factor: 2.957

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.